Key result
Ticagrelor was not associated with a significant difference in in-hospital all-cause mortality (HR 1.04) or major bleeding compared to clopidogrel in patients with STEMI complicated by cardiogenic shock undergoing primary PCI.
Why the study?
Although ticagrelor is recommended over clopidogrel in STEMI undergoing pPCI, evidence is limited in patients with cardiogenic shock.
Does ticagrelor improve in-hospital all-cause mortality and major bleeding compared to clopidogrel in patients with STEMI complicated by cardiogenic shock undergoing primary PCI?
Cohort (n=729)
Yes
Does ticagrelor improve in-hospital all-cause mortality and major bleeding compared to clopidogrel in patients with STEMI complicated by cardiogenic shock undergoing primary PCI?
Hazard Ratio: 1.04 (95% CI 0.69–1.56)
Absolute Event Rate: 13.5% vs 14.64%
p-value: p=0.840
In patients with STEMI complicated by cardiogenic shock undergoing primary PCI, ticagrelor and clopidogrel showed no significant difference in in-hospital mortality or major bleeding, suggesting both are feasible options.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction complicated by cardiogenic shock (STEMI-CS) (n=729). Ticagrelor vs. Clopidogrel was evaluated on In-hospital all-cause mortality (HR 1.04, 95% CI 0.69-1.56, p=0.840). Ticagrelor was not associated with a significant difference in in-hospital all-cause mortality (HR 1.04) or major bleeding compared to clopidogrel in patients with STEMI complicated by cardiogenic shock undergoing primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: